🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

86 results for “TG” Clear

  1. ABIRATERONE ACETATE, DAROLUTAMIDE, Locametz 25 micrograms kit for radiopharmaceutical preparation, APALUTAMIDE, Pluvicto 1 000 MBq/mL solution for injection/infusion, ENZALUTAMIDE

    Cancer Prevention Pharma (Ireland) Limited

    Novo metastatic hormone-sensitive prostate cancer (mHSPC) patients having a serum PSA level of ≥ 0.2 ng/mL at 6 to 8 months after systemic treatment initiation for mHSPC (i.e. poor responders) in the absence of evidence of cancer progression (including a rising PSA level)

    phase 3 small molecule active

    1 trial

  2. ARO-APOC3 PFS

    Arrowhead Pharmaceuticals Ireland Limited

    Hypertriglyceridemia (HTG)

    phase 3 small molecule active

    1 trial

  3. ARO-APOC3 PFS, Plozasiran Injection Placebo

    Arrowhead Pharmaceuticals Ireland Limited

    Severe hypertriglyceridemia (SHTG)

    phase 3 small molecule active

    1 trial

  4. BAY 1841788, TRIPTORELIN

    Cancer Prevention Pharma (Ireland) Limited

    Patients with localised prostate cancer and high-risk features of relapse (minimum 2 high-risk criteria from National Comprehensive Cancer Network (NCCN) classification)1 and with no detectable metastasis, including no evidence of pelvic lymph node metastasis on next-generation imaging (PSMA PET/CT).

    phase 3 small molecule active

    1 trial

  5. Fingolimod placebo, FINGOLIMOD, Ublituximab Placebo, ublituximab

    TG THERAPEUTICS, INC.

    Relapsing Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  6. LEUPRORELIN ACETATE, BAY 1841788, NUBEQA 300 mg film-coated tablets, TRIPTORELIN, DEGARELIX, GOSERELIN

    Cancer Prevention Pharma (Ireland) Limited

    Castrate-resistant prostate cancer with oligometastases on functional imaging (PSMA or choline/fluciclovine-positron-emission tomography).

    phase 3 small molecule active

    1 trial

  7. LOMUSTINE

    Cancer Prevention Pharma (Ireland) Limited

    Glioblastoma

    phase 3 small molecule active

    1 trial

  8. Lynparza 150 mg film-coated tablets, IBRANCE 125 mg hard capsules, Lynparza 100 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., Tabrecta 200 mg film-coated tablets, Daurismo 100 mg film-coated tablets, Mekinist 0.5 mg film-coated tablets, Tabrecta 150 mg film-coated tablets, Lytgobi 4 mg film-coated tablets, Mekinist 2 mg film-coated tablets, IBRANCE 100 mg hard capsules, Tyverb 250 mg film-coated tablets, Tafinlar 75 mg hard capsules, Zykadia 150 mg hard capsules, IBRANCE 7

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Unresectable locally advanced and/or metastatic soft-tissue sarcoma

    phase 3 small molecule active

    1 trial

  9. Obinutuzumab

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 3 mab terminated

    1 trial

  10. Placebo tablets to match S95032 drug product are supplied as film-coated tablets for oral administration., S95032/AG-881, S95032/AG-881

    Cancer Prevention Pharma (Ireland) Limited

    ​​IDH-mutant grade 2 or 3 astrocytoma​

    phase 3 small molecule active

    1 trial

  11. Placebo to Basimglurant (Microcrystalline Cellulose Spheres (Vivapur 1000) and hard Gelatin Capsule, Opaque white body/Opaque white cap, Size 1), Basimglurant, Basimglurant

    Pharma Mar S.A.

    Trigeminal neuralgia, Trigeminal neuralgia

    phase 3 small molecule active

    1 trial

  12. Plozasiran Injection Placebo, ARO-APOC3 PFS

    Arrowhead Pharmaceuticals Ireland Limited

    Severe hypertriglyceridemia (SHTG)

    phase 3 small molecule active

    1 trial

  13. Plozasiran Injection Placebo, ARO-APOC3 PFS

    Arrowhead Pharmaceuticals Ireland Limited

    Severe hypertriglyceridemia (SHTG)

    phase 3 small molecule active

    1 trial

  14. Rusfertide 45mg, Rusfertide 60mg, Rusfertide 30mg, Rusfertide 10mg, Rusfertide 20mg, Placebo to Match PTG-300 for Injection. Formulation (lyophilized powder) is based upon that of PTG-300 for Injection, with the drug substance omitted.

    Protagonist Therapeutics, Inc

    Polycythemia Vera

    phase 3 small molecule active

    1 trial

  15. Ublituximab

    TG THERAPEUTICS, INC.

    Relapsing Multiple Sclerosis

    phase 3 small molecule active

    3 trials

  16. Ublituximab

    TG THERAPEUTICS, INC.

    Diffuse Large B-Cell Lymphoma

    phase 3 mab terminated

    1 trial

  17. Ublituximab

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 3 small molecule completed

    5 trials

  18. Ublituximab

    TG THERAPEUTICS, INC.

    Relapsing Multiple Sclerosis (RMS)

    phase 3 mab active

    3 trials

  19. Ublituximab, ublituximab

    TG THERAPEUTICS, INC.

    Relapsing forms of Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  20. ublituximab

    TG THERAPEUTICS, INC.

    relapsing multiple sclerosis

    phase 3 small molecule active

    1 trial

  21. ublituximab, DEXAMETHASONE, PARACETAMOL, GADOBUTROL, ublituximab placebo, DIPHENHYDRAMINE, CETIRIZINE, METHYLPREDNISOLONE

    TG THERAPEUTICS, INC.

    Relapsing multiple sclerosis

    phase 3 small molecule active

    1 trial

  22. Acalabrutinib

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  23. An Adaptive Dose Escalation and Expansion Basket Trial to Explore the Safety, Pharmacology, and Clinical Activity of TGD001 in Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP) and Other Thrombotic Microangiopathies

    Pharma Mar S.A.

    Immune-Mediated Thrombotic Thrombocytopenic Purpura, Thrombotic microangiopathy

    phase 2 other active

    1 trial

  24. Antithymocyte globulin (ATG)

    Ultragenyx UK Limited

    Myelodysplastic Syndrome

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources